Ringler Radio, a popular radio program conducted by the nation’s largest structured settlement company, Ringler Associates, introduced Beasley Allen attorneys Andy Birchfield and Leigh O’Dell to discuss their progress on litigation involving Actos, Transvaginal Mesh and Zohydro. Actos is a prescription medication for type-2 diabetes or adult-onset diabetes. One of many drugs used to treat diabetes, Actos distinguishes itself by being from a class of drugs known as TZDs. TZDs have been the culprit of many problems in the past, such as with the diabetes drug Resulin, which was pulled off the market after causing liver failure and many deaths in its users. Actos has been linked to the development of bladder cancer. Transvaginal mesh is separated into two types of products: one is used to treat pelvic organ prolapse (POP) and the other for stress urinary incontinence. Due to the use of this dangerous mesh, millions of women are forced to live in constant internal pain from the erosion of the mesh within them. Birchfield and O’Dell also talked about emerging concerns about the painkiller Zohydro. Manufactured by Zogenix Inc., Zohydro is a painkiller with between five and 10 times more of the semi-synthetic opioid hydrocodone than common painkillers including Vicodin and Lortab. However, the Zohydro lacks any abuse deterrents that have been built into newer painkillers.
May 19, 2014